[go: up one dir, main page]

EA200400591A1 - СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1 - Google Patents

СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1

Info

Publication number
EA200400591A1
EA200400591A1 EA200400591A EA200400591A EA200400591A1 EA 200400591 A1 EA200400591 A1 EA 200400591A1 EA 200400591 A EA200400591 A EA 200400591A EA 200400591 A EA200400591 A EA 200400591A EA 200400591 A1 EA200400591 A1 EA 200400591A1
Authority
EA
Eurasian Patent Office
Prior art keywords
administrating
peptide
peptide thymosin
patient
thymosin
Prior art date
Application number
EA200400591A
Other languages
English (en)
Other versions
EA008536B1 (ru
Inventor
Алфред Р. Рудолф
Синтия У. Татхилл
Original Assignee
Сциклон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сциклон Фармасьютикалс, Инк. filed Critical Сциклон Фармасьютикалс, Инк.
Publication of EA200400591A1 publication Critical patent/EA200400591A1/ru
Publication of EA008536B1 publication Critical patent/EA008536B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Пептид тимозин α(TA1) вводят пациенту, нуждающемуся в иммунной стимуляции таким образом, чтобы по сути непрерывно поддерживать иммуностимулирующее эффективное количество пептида TA1 у пациента. Способом введения может быть непрерывная инфузия.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400591A 2001-11-01 2002-11-01 СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИНА α EA008536B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087401P 2001-11-01 2001-11-01
PCT/US2002/035093 WO2003037366A1 (en) 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide

Publications (2)

Publication Number Publication Date
EA200400591A1 true EA200400591A1 (ru) 2004-10-28
EA008536B1 EA008536B1 (ru) 2007-06-29

Family

ID=23291672

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400591A EA008536B1 (ru) 2001-11-01 2002-11-01 СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИНА α

Country Status (19)

Country Link
US (2) US20050049191A1 (ru)
EP (1) EP1450850B1 (ru)
JP (1) JP2005511563A (ru)
KR (1) KR20050042229A (ru)
CN (1) CN1582163A (ru)
AT (1) ATE481980T1 (ru)
AU (1) AU2002363248B2 (ru)
BR (1) BR0213823A (ru)
CA (1) CA2464307A1 (ru)
DE (1) DE60237784D1 (ru)
EA (1) EA008536B1 (ru)
ES (1) ES2353379T3 (ru)
IL (2) IL161665A0 (ru)
MX (1) MXPA04004187A (ru)
NO (1) NO327101B1 (ru)
NZ (1) NZ532763A (ru)
PL (1) PL208388B1 (ru)
UA (1) UA80957C2 (ru)
WO (1) WO2003037366A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100501400C (zh) * 2002-11-25 2009-06-17 希克龙制药公司 使用α胸腺素防护辐射损伤的方法
DK1613340T3 (da) 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
WO2013134666A1 (en) * 2012-03-08 2013-09-12 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
US20130296223A1 (en) 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
SG11201702558VA (en) 2014-10-21 2017-05-30 Sciclone Pharmaceuticals Inc Treatment of cancer with immune stimulators
WO2016129005A1 (en) 2015-02-09 2016-08-18 Luigina Romani Thymosin alpha 1 for use in treatment of cystic fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (ru) * 1991-09-13 1994-05-21 Paul B Chretien
TW249754B (ru) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5849596A (en) * 1996-07-08 1998-12-15 Food Industry Research And Development Institute Process for determining the smoke content of edible oil
AU2001277887B2 (en) * 2000-07-14 2006-09-14 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
CA2427430A1 (en) * 2000-11-02 2002-06-13 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4

Also Published As

Publication number Publication date
PL370430A1 (en) 2005-05-30
US20050049191A1 (en) 2005-03-03
ES2353379T3 (es) 2011-03-01
PL208388B1 (pl) 2011-04-29
BR0213823A (pt) 2004-08-31
ATE481980T1 (de) 2010-10-15
NO20042100D0 (no) 2004-05-21
EP1450850A4 (en) 2005-11-30
US20100221274A1 (en) 2010-09-02
AU2002363248B2 (en) 2007-11-22
WO2003037366A1 (en) 2003-05-08
EP1450850A1 (en) 2004-09-01
IL161665A0 (en) 2004-09-27
MXPA04004187A (es) 2004-07-08
DE60237784D1 (de) 2010-11-04
CA2464307A1 (en) 2003-05-08
EA008536B1 (ru) 2007-06-29
NO327101B1 (no) 2009-04-20
CN1582163A (zh) 2005-02-16
IL161665A (en) 2011-03-31
KR20050042229A (ko) 2005-05-06
NZ532763A (en) 2008-01-31
NO20042100L (no) 2004-05-21
UA80957C2 (en) 2007-11-26
JP2005511563A (ja) 2005-04-28
EP1450850B1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
DK0490991T3 (da) Doseringsform til oral administration af hypoglykæmisk glipizid
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
NO306377B1 (no) Doseform for avgivelse av et medikament
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
EP1680110A4 (en) DAILY DOSED FORM OF TROSPIUM
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
EA200400591A1 (ru) СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
DE60031259D1 (de) Nährstoffe aus sojabohnenprotein
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
TW200517119A (en) Method of treatment using interferon-tau
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
KR927003083A (ko) 인간 인터류킨 2 활성을 갖는 폴리펩티드 기재의 항종양제 조성물
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드
RU2004105675A (ru) Способ комплексного лечения язв роговицы
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
RU2001104929A (ru) Способ лечения рассеянного склероза
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG MD RU